新辅助免疫治疗成为最佳医疗实践,并将成为大体量III期黑色素瘤的新标准治疗
本文综述大体量III期黑色素瘤的治疗现状与新辅助免疫治疗证据:单纯手术5年总生存率40-59%、无复发生存率30-39%,当前标准为治疗性淋巴结清扫(TLND)后1年辅助系统治疗;多项2期试验显示新辅助免疫治疗可诱导主要病理缓解(MPR)并转化为持久无复发生存,作者认为其临床优于辅助治疗,应列为最佳医疗实践。
要点
- 单纯手术5年总生存率40-59%、无复发生存率30-39%,当前标准为TLND后1年辅助系统治疗。
- 单药抗PD-1的MPR为20-30%,伊匹木单抗联合纳武利尤单抗使MPR倍增至50-60%。
- S1801期中分析中位随访14个月观察到23%的EFS率获益,支持新辅助优于辅助治疗。
核心结论
- 作者认为快速、一致且不断积累的1期和2期试验证据表明,新辅助免疫治疗在大体量III期黑色素瘤中临床优于辅助系统治疗。
- 作者提出付款方应考虑将新辅助免疫治疗纳入报销,并将该方式归类为最佳医疗实践。
研究设计与样本
- 本文为叙述性综述,汇总1期与2期试验、OpACIN试验、随机2期S1801期中结果及正在进行的3期NADINA试验。
- 当前标准治疗为治疗性淋巴结清扫(TLND)后行1年辅助系统治疗。
主要发现
- 单纯手术的5年总生存率为40-59%,5年无复发生存率为30-39%。
- 单药抗PD-1的MPR为20-30%,伊匹木单抗联合纳武利尤单抗使MPR倍增至50-60%。
- OpACIN试验显示,与辅助免疫治疗相比,新辅助免疫治疗在外周血中诱导出数量更多、谱系更广的肿瘤驻留T细胞。
- S1801随机2期试验比较TLND后18程辅助帕博利珠单抗与3程新辅助帕博利珠单抗后手术再15剂辅助治疗,中位随访14个月观察到23%的EFS率获益。
- 正在进行的3期NADINA试验将患者随机分为TLND+1年辅助纳武利尤单抗(对照组)或2程伊匹木单抗联合纳武利尤单抗新辅助治疗后仅对非MPR患者行辅助治疗。
关键数值与推荐
- MPR定义:病理完全缓解(pCR)为0%存活肿瘤细胞;近pCR为<10%存活肿瘤细胞。
- 单纯手术5年总生存率40-59%、5年无复发生存率30-39%。
- 单药抗PD-1的MPR为20-30%;伊匹木单抗联合纳武利尤单抗的MPR为50-60%。
- S1801中位随访14个月,EFS率获益为23%。
临床怎么用
- 作者认为新辅助免疫治疗是大体量III期黑色素瘤患者的最佳选择,应归类为最佳医疗实践。
- 作者提出付款方应考虑将新辅助免疫治疗纳入报销。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively. The current standard of care is therapeutic lymph node dissection (TLND) followed by a year of adjuvant systemic therapy. Multiple phase 2 trials have shown that neo-adjuvant immunotherapy induces major pathologic response (MPR) rates (pathologic complete response (pCR): pCR, 0% viable tumour cells; near-pCR, <10% viable tumour cells), which translate into durable relapse free survival rates. Single agent anti-PD-1 achieves 20-30% MPR, the combination of ipilimumab and nivolumab doubles the MPR rates to 50-60%. The OpACIN trial demonstrated that neoadjuvant immunotherapy induced both higher numbers and a broader repertoire of tumour-resident T-cells in peripheral blood compared with adjuvant immunotherapy. Very recently, the randomised phase 2 trial S1801 reported its first interim results. S1801 compared TLND, followed by 18 courses of adjuvant pembrolizumab, to three courses of neoadjuvant pembrolizumab, followed by surgery and 15 adjuvant doses. With a median follow-up of 14 months, a 23% EFS rate benefit was observed. The ongoing phase 3 NADINA trial randomises patients between TLND + one year of adjuvant nivolumab (control arm) or 2 courses of neoadjuvant therapy with ipilimumab + nivolumab, followed by adjuvant therapy only for non-MPR patients. There is rapid, consistent, and accumulating evidence generated from all phase 1 and phase 2 trials, indicating clinical superiority of neoadjuvant immunotherapy over adjuvant systemic therapy for macroscopic stage III melanoma. Therefore, payers should consider neoadjuvant immunotherapy for reimbursement as this approach is the best option for our patients, and classify it as the best medical practice.
引用
- van Akkooi ACJ, Blank C, Eggermont AMM, et al. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. Eur J Cancer. 2023. PMID: 36738540. doi:10.1016/j.ejca.2023.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。